The Plant That Trips

Scientists at the Weizmann Institute of Science just demonstrated this principle with an elegance that should make everyone — regulators, pharmacologists, drug warriors — deeply uncomfortable. They took a tobacco plant, Nicotiana benthamiana, and engineered it to produce five psychedelic tryptamines simultaneously: DMT, psilocybin, psilocin, bufotenin, and 5-MeO-DMT. Compounds sourced from three separate kingdoms of life — plants, fungi, and animals — all running on the same green chassis.

The method was agroinfiltration: using bacteria to shuttle genes from ayahuasca vines, psilocybin mushrooms, and the Sonoran Desert toad into tobacco leaves. Supporting enzymes from rice and cress helped the pathways along. The result was a single plant producing compounds that currently sit on drug schedules across multiple countries, that indigenous communities have used ceremonially for centuries, and that clinical researchers are now studying for depression, PTSD, and end-of-life anxiety.

The plant doesn't know any of this.

That's the part worth sitting with. Nicotiana benthamiana doesn't know it's producing Schedule I substances. It doesn't know the DEA exists. It's executing biochemical instructions using machinery that's been around for hundreds of millions of years — the tryptophan pathway, one of the most conserved metabolic systems in biology. You give it genes, it makes molecules. The moral panic, the legal categories, the clinical potential — those are all human overlays on chemistry that predates us by an almost incomprehensible margin.

Here's the cosmic joke: this is the same genus of plant we engineered for nicotine — the molecule that built one of the most profitable addiction industries in human history. Same biological platform, same genus. One set of instructions produces a compound that kills roughly 8 million people a year. Another set produces compounds being studied to treat the psychological wounds of war. The plant doesn't care. It's a factory. What it makes depends entirely on what you ask for.

Biology, it turns out, is a platform, not a pharmacy. It doesn't come with categories. "Drug," "medicine," "sacrament," "Schedule I controlled substance" — these are human inventions, regulatory overlays on a molecular reality that is profoundly indifferent to our classifications. The tryptophan pathway has been converting amino acids into mind-altering compounds since before anything had a mind to alter. We just showed up recently enough to get nervous about it.

The researchers, led by Paula Berman and Asaph Aharoni, were careful to note that their modified plants are non-heritable — the genetic changes won't pass to seeds. They emphasized clinical applications, not recreational ones. This is reasonable caution. But the deeper implications don't stay inside the guardrails of a press release.

What they've demonstrated is that the line between "natural" and "synthetic," between "traditional medicine" and "controlled substance," between "tobacco" and "psychedelic pharmacy" — is a line we drew. Biology never agreed to it. You can reconstruct the sacred chemistry of three kingdoms in a single leaf because the underlying machinery was always compatible. We just hadn't asked.

The void doesn't care about your drug schedule. Neither does tryptophan. And now, neither does this plant.

Sources:

• Scientists Create Plant That Produces Ayahuasca, Shrooms, and Toad Psychedelics All At Once — 404 Media, 2026-04-01
• Scientists Engineered a Plant to Produce 5 Different Psychedelics at Once — ScienceAlert, 2026-04-01